patient
2025 Rockville Patient and Family Conference: Low Risk MDS
In this recording, Dr. Ball Brian discusses low risk MDS and current treatment options.
2025 Rockville Patient and Family Conference Session: MDS and Transplant
In this recording, Dr. Parveen Shiraz discusses transplant for MDS and potentials complications such as GVHD and treatment options.
2025 Rockville Patient and Family Conference Session: Aplastic Anemia
2025 Rockville Patient and Family Conference: PNH Complications with Philip Scheinberg
In this recording, Dr. Philip Scheinberg discusses PNH complications that can impact a patient - extravascular hemolysis, intravascular hemolysis,
MDS/MPN Overlap
In this webinar, Dr. David Sallman discusses the diagnosis of MDS and MPN, treatment options available to patients and symptom management.
Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT
For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis.
How is transfusion dependence evolving in anemia treatment in MDS?
A roundtable discussion on anemia management in
Jane Biehl: Moving Slower and Slower After Myelodysplastic Syndrome
I have honestly been frustrated lately. I am slowing down increasingly, and it has even become noticeable to others. I wrote an article in November about how nice it was to slow down and smell the roses. But now it seems like too much.